Story Highlight
– Pregnant women often excluded from clinical trials historically.
– Evidence gaps lead to anxiety and inconsistent medical advice.
– BPS calls for inclusive research and clearer risk communication.
– Inclusion could improve safety and efficacy of medications.
– Current efforts focus on overcoming barriers to participation.
Full Story
In a significant development for women’s health, experts are calling for improved inclusion of pregnant and breastfeeding women in clinical research. This urgency follows decades of their exclusion from studies, often due to ethical concerns about potential harm to both mothers and their babies. As a result, there is a considerable void in reliable data regarding the safety and efficacy of medications used during pregnancy and lactation.
Professor Asma Khalil, a leading authority in Obstetrics and Maternal Medicine at City St George’s, University of London, articulated the dilemma faced by healthcare professionals. She emphasized that the lack of robust evidence leaves many women navigating their treatment decisions amid uncertainty. “Too often, pregnant and breastfeeding women are left making decisions about medicines in the absence of robust evidence,” she stated. “This can lead to anxiety, inconsistent advice, undertreatment of important maternal conditions, and poorer outcomes for women and babies.”
The British Pharmacological Society (BPS) has recently echoed these sentiments in a position statement, advocating for a drastic overhaul in research practices to ensure that pregnant and breastfeeding women are considered in clinical trials. The statement revealed that in the UK, over 80% of women take at least one medication during pregnancy or while breastfeeding, yet the research supporting safe prescribing for this group remains disturbingly inadequate.
Historically, one of the major barriers to inclusion in research has been the ethical and legal concerns surrounding trials involving pregnant and breastfeeding populations. This cautious approach, while understandable, has resulted in a cultural norm that many experts agree can no longer be justified. “Blanket exclusion is no longer acceptable,” Professor Khalil commented, stressing the significant risks posed by poorly controlled maternal health issues, including the dangers of untreated conditions that could adversely affect both mothers and their infants.
Dr Victoria Male, an Associate Professor at Imperial College London specializing in Reproductive Immunology, highlighted the challenges in advancing the inclusion of pregnant women in clinical research. She noted that although recognition of the importance of such research exists among patients and healthcare providers, external barriers such as high insurance costs due to potential safety issues often discourage trial sponsors from including this cohort. “Trial sponsors and insurers can be more of a barrier,” Dr Male explained, reinforcing the need for strong recommendations from regulatory authorities to advocate for the inclusion of pregnant participants in clinical studies.
Dr Male cited the RECOVERY trial, a national COVID-19 study, as a positive example of successful participation by pregnant women, where 110 opted in based on comprehensive assessments of risk and benefit provided by the research team. This proactive approach included collaboration with maternal health surveillance teams, which ensured that potential risks of not providing treatments to severely ill pregnant patients were adequately considered.
The call for change extends beyond individual studies. It highlights the pressing need for a regulatory shift both in the UK and internationally to facilitate a more inclusive approach. The BPS has called for clear guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) and other authorities to mandate the inclusion of pregnant and breastfeeding populations in clinical trials and ensure that their unique risks are not overlooked.
Dr Christopher Rentsch from the London School of Hygiene and Tropical Medicine reiterated the necessity for women involved in trials. “Women should be considered in the trials of products likely to be used during pregnancy and breastfeeding,” he commented, stressing that while the absence of safe prescribing information has raised concerns among women, many medications are actually safe when documented properly.
The historical foundation for excluding pregnant women from clinical research can be traced back to the thalidomide tragedy of the late 1950s, which drastically shifted perspectives on medical research ethics. However, reliance on exclusion has inadvertently eliminated critical data necessary for informed treatment decisions, particularly affecting the 90% of pregnant women with chronic conditions who still require medication.
Dr Hazel Spencer from Bournemouth University emphasized that despite ethical safeguards, the absence of adequate research often forces clinicians into a precarious position where they must recommend treatments without comprehensive data. “This protective approach has created a significant gap in the evidence base for medicines used during pregnancy and breastfeeding,” she remarked.
To combat lingering issues in recruitment and participation among pregnant and breastfeeding women, experts call for a multi-faceted effort aimed at not only addressing regulatory challenges but also changing the narrative around women’s health. Professor Penny Ward highlighted the importance of building patient trust to encourage participation in drug studies, particularly for medications specifically developed for pregnancy-related health issues.
In her comments, Professor Louise Kenny of the University of Liverpool noted the broader implications of this exclusionary history. “Women have been excluded from every step of the drug development pipeline,” she asserted, linking this lack of representation directly to inadequate treatment options for various women’s health issues, including conditions like endometriosis and polycystic ovarian syndrome.
The positive momentum triggered by the BPS’s position statement brings hope. Naho Yamazaki from the Health Research Authority noted their initiative in promoting inclusive research practices, developing guiding documents to foster diversity in clinical trials while aligning with the BPS’s recommendations.
The acknowledgment from various health leaders that the historical exclusion of pregnant and breastfeeding women must be addressed represents a shift in focus towards a more inclusive and evidence-driven approach in clinical research. As women’s health receives renewed attention, the need for equitable representation in study cohorts cannot be understated. By ensuring that pregnant and breastfeeding women are included in research, the medical community can improve not only the health outcomes for women and their babies but also enhance public confidence in the treatments available to them.
Our Thoughts
The article highlights the exclusion of pregnant and breastfeeding women from clinical trials, leading to a significant lack of evidence on medication safety and efficacy in this demographic. To avoid similar outcomes in the future, several key safety lessons and actionable recommendations emerge:
1. **Regulatory Framework Improvement**: The Medicines and Healthcare products Regulatory Agency (MHRA) must enforce regulations requiring the inclusion of pregnant and breastfeeding women in clinical trials, moving away from the historic culture of exclusion that raises ethical concerns.
2. **Robust Risk Assessment Protocols**: Implementing robust protocols for evaluating the risks and benefits of including pregnant participants, as demonstrated by the RECOVERY trial, would provide clearer guidance, fulfilling the requirements set by UK legislation on clinical research.
3. **Stakeholder Education**: Enhancing education for healthcare professionals about the safe use of medications during pregnancy and breastfeeding could mitigate unjustified anxiety leading to treatment discontinuation which might violate the Health and Safety at Work Act 1974 by failing to provide adequate support for patient health.
4. **Encouraging Data Collection**: Pharmaceutical companies should be mandated to follow up on pregnancy outcomes in women taking their medications, reinforcing responsibilities in line with UK health surveillance laws.
By addressing these areas through regulatory changes and better risk communication, healthcare outcomes for pregnant and breastfeeding women can be significantly improved, minimizing preventable health risks.
